Effect of Exercise on Irisin Levels of Hypothyroid Rats

NCT ID: NCT06699069

Last Updated: 2024-11-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-02-20

Study Completion Date

2022-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of study was to evaluate the role of exercise on serum irisin levels in hypothyroid rats.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Contracting skeletal muscle acts as an endocrine organ, capable of secreting hormones called myokines, such as interleukin 1, Interleukin 15 and Irisin. Myokines are important for regulation of glucose and lipid metabolism. Among these, irisin, is an exercise induced polypeptide, secreted mainly by skeletal muscles and adipose tissue. Irisin is also secreted in small amounts from cardiac muscle, pancreas and sebaceous glands. It is cleaved and secreted from fibronectin type III domain-containing protein 5 (FNDC5 gene) and is regulated by the peroxisome proliferator-activated receptor-γ co activator 1-α (PGC1-α) .

The most important function of Irisin is thermogenesis, by inducing the browning of white adipose tissue, thereby increasing energy consumption, encouraging weight loss and decreasing dietary insulin resistance. Linking Irisin levels with obesity, its mechanism shows that after exercise there is up regulation of a thermogenin ,an Uncoupling Protein-1 (UCP-1) Thyroid hormone also plays an important role in glucose-lipid metabolism and energy homeostasis. Hypothyroidism, a decrease in thyroid hormone levels, can lead to obesity and metabolic syndrome. It has been found that thyroid hormone is also involved in thermogenesis by inducing browning of white adipose tissue, through thyroid hormone receptors. In hypothyroidism, many metabolic processes in the body are affected such as differentiation in the adipose tissue. Increased thyroid stimulating hormone (TSH) causes adipogenesis by stimulating pre-adipocyte differentiation directly through the receptors in the adipose tissue . Fatty tissue is increased by adipocyte hypertrophy as a consequence of previous adipogenesis, and newly formed adipocyte-8, resulting in clinical obesity.

FNDC5 (Fibronectin type III domain-containing protein 5), which is the precursor of irisin, is a protein that is encoded by the FNDC5 gene, is present in many tissues, including the thyroid tissue and therefore effects thyroid hormone.

Dysregulation of both Thyroid and Irisin hormones result in metabolic syndrome. The metabolic syndrome is a common metabolic disorder that has been linked to the increasing prevalence of obesity. By regulating thyroid hormone levels, irisin has a powerful impact on metabolism and thermogenesis. The association of irisin with the thyroid hormone in hypothyroidism still remains unknown and is controversial, and requires further confirmatory studies on experimental models.

Regular exercise is known to have significant beneficial effects on the metabolic health and this is mediated by skeletal muscle. Contracting skeletal muscle is the source of Irisin. Studies have shown an increase in post exercise Irisin levels

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypothyroidism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I (Control or Euthyroid) total number of rats=20

Fed on normal standard diet

Group Type EXPERIMENTAL

Control or Euthyroid group

Intervention Type OTHER

Fed on normal standard diet

Group II (Hypothyroid) total number of rats=20

Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water

Group Type EXPERIMENTAL

Hypothyroid group

Intervention Type OTHER

Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water

Group III (Hypothyroid received exercise) total number of rats=20

Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise.

Group Type EXPERIMENTAL

Hypothyroid group received exercise

Intervention Type OTHER

Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Control or Euthyroid group

Fed on normal standard diet

Intervention Type OTHER

Hypothyroid group

Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water

Intervention Type OTHER

Hypothyroid group received exercise

Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male adult rats weighing approx. 200-250gms
* 6 to 8 week old rats

Exclusion Criteria

* Female rats will be excluded.
* Rats with any obvious pathology
* The rats weighing \>200gm
Minimum Eligible Age

6 Weeks

Maximum Eligible Age

8 Weeks

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Riphah International University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Shazia Ali, PhD

Role: PRINCIPAL_INVESTIGATOR

Riphah International University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

National Institute of Health

Islamabad, Federal, Pakistan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Pakistan

References

Explore related publications, articles, or registry entries linked to this study.

Martinez Munoz IY, Camarillo Romero EDS, Garduno Garcia JJ. Irisin a Novel Metabolic Biomarker: Present Knowledge and Future Directions. Int J Endocrinol. 2018 Oct 9;2018:7816806. doi: 10.1155/2018/7816806. eCollection 2018.

Reference Type BACKGROUND
PMID: 30402097 (View on PubMed)

Korta P, Pochec E, Mazur-Bialy A. Irisin as a Multifunctional Protein: Implications for Health and Certain Diseases. Medicina (Kaunas). 2019 Aug 15;55(8):485. doi: 10.3390/medicina55080485.

Reference Type BACKGROUND
PMID: 31443222 (View on PubMed)

Gizaw M, Anandakumar P, Debela T. A Review on the Role of Irisin in Insulin Resistance and Type 2 Diabetes Mellitus. J Pharmacopuncture. 2017 Dec;20(4):235-242. doi: 10.3831/KPI.2017.20.029. Epub 2017 Oct 10.

Reference Type BACKGROUND
PMID: 30151293 (View on PubMed)

Uc ZA, Gorar S, Mizrak S, Gullu S. Irisin levels increase after treatment in patients with newly diagnosed Hashimoto thyroiditis. J Endocrinol Invest. 2019 Feb;42(2):175-181. doi: 10.1007/s40618-018-0899-8. Epub 2018 May 18.

Reference Type BACKGROUND
PMID: 29777516 (View on PubMed)

Maalouf GE, El Khoury D. Exercise-Induced Irisin, the Fat Browning Myokine, as a Potential Anticancer Agent. J Obes. 2019 Apr 1;2019:6561726. doi: 10.1155/2019/6561726. eCollection 2019.

Reference Type BACKGROUND
PMID: 31065382 (View on PubMed)

Deshmukh V, Farishta F, Bhole M. Thyroid Dysfunction in Patients with Metabolic Syndrome: A Cross-Sectional, Epidemiological, Pan-India Study. Int J Endocrinol. 2018 Dec 25;2018:2930251. doi: 10.1155/2018/2930251. eCollection 2018.

Reference Type BACKGROUND
PMID: 30675157 (View on PubMed)

Abdel Moety DA. Evaluation of Serum Irisin and Creatine Kinase Levels in Hypo- and Hyperthyroid Rats. Al-Azhar Med J. 2017;46(1):163-74.

Reference Type BACKGROUND

Ates I, Altay M, Topcuoglu C, Yilmaz FM. Circulating levels of irisin is elevated in hypothyroidism, a case-control study. Arch Endocrinol Metab. 2016 Apr;60(2):95-100. doi: 10.1590/2359-3997000000077. Epub 2015 Jul 21.

Reference Type BACKGROUND
PMID: 26201007 (View on PubMed)

Yang N, Zhang H, Gao X, Miao L, Yao Z, Xu Y, Wang G. Role of irisin in Chinese patients with hypothyroidism: an interventional study. J Int Med Res. 2019 Apr;47(4):1592-1601. doi: 10.1177/0300060518824445. Epub 2019 Feb 6.

Reference Type BACKGROUND
PMID: 30722716 (View on PubMed)

Rochlani Y, Pothineni NV, Kovelamudi S, Mehta JL. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017 Aug;11(8):215-225. doi: 10.1177/1753944717711379. Epub 2017 Jun 22.

Reference Type BACKGROUND
PMID: 28639538 (View on PubMed)

Teixeira PFDS, Dos Santos PB, Pazos-Moura CC. The role of thyroid hormone in metabolism and metabolic syndrome. Ther Adv Endocrinol Metab. 2020 May 13;11:2042018820917869. doi: 10.1177/2042018820917869. eCollection 2020.

Reference Type BACKGROUND
PMID: 32489580 (View on PubMed)

Kurdiova T, Balaz M, Vician M, Maderova D, Vlcek M, Valkovic L, Srbecky M, Imrich R, Kyselovicova O, Belan V, Jelok I, Wolfrum C, Klimes I, Krssak M, Zemkova E, Gasperikova D, Ukropec J, Ukropcova B. Effects of obesity, diabetes and exercise on Fndc5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 2014 Mar 1;592(5):1091-107. doi: 10.1113/jphysiol.2013.264655. Epub 2013 Dec 2.

Reference Type BACKGROUND
PMID: 24297848 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRC/20/232 Fatima Iqbal

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Iodine Supplementation in Graves' Hyperthyroidism
NCT06540469 NOT_YET_RECRUITING NA
Walking for Hypothyroidism Trial (WHT)
NCT07205042 NOT_YET_RECRUITING NA
Iodine Supplementation in Obesity
NCT01985204 COMPLETED NA